These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19117960)

  • 21. Adjunctive pharmacotherapy for coronary interventions-time to read the writing on the wall.
    Kaluski E; Hendler A; Uriel N; Milo-Cotter O; Vered Z; Krakover R; Cotter G
    Acute Card Care; 2006; 8(4):186-95. PubMed ID: 17162545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.
    Kaeberich A; Raaz U; Vogt A; Maedgefessel L; Neuhart E; Krezel C; Drouget L; Hauroeder B; Buerke M; Werdan K; Schlitt A
    J Thromb Thrombolysis; 2014; 37(2):118-30. PubMed ID: 23821043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Direct and indirect antithrombins in acute coronary syndromes].
    Höchtl T; Geppert A; Nürnberg M; Unger G; Speidl W; Wojta J; Huber K
    Wien Klin Wochenschr; 2005 Dec; 117(23-24):792-800. PubMed ID: 16437314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials.
    Cohen M
    Am J Med; 2010 Feb; 123(2):103-10. PubMed ID: 20103015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antiplatelets and anticoagulants in acute coronary syndromes: levels of evidence].
    Páramo JA; García R; Rodríguez P; de Gaona ER
    Rev Med Univ Navarra; 2007; 51(1):23-7. PubMed ID: 17555117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New antithrombotic drugs: potential for use in oncology.
    Levine MN
    J Clin Oncol; 2009 Oct; 27(29):4912-8. PubMed ID: 19738103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
    Karthikeyan G; Mehta SR; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):241-9. PubMed ID: 19296760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study.
    Maegdefessel L; Buerke M; Schubert S; Reindl I; Michel T; Hauroeder B; Carter JM; Peetz D; Werdan K; Schlitt A
    Thromb Haemost; 2008 Oct; 100(4):693-8. PubMed ID: 18841294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026.
    Viskov C; Just M; Laux V; Mourier P; Lorenz M
    J Thromb Haemost; 2009 Jul; 7(7):1143-51. PubMed ID: 19422447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.
    Baker WL; White CM
    Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New parenteral anticoagulants in development.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Rocha E; Pozo-Hernández C; Vargas-Castrillón E
    Ther Adv Cardiovasc Dis; 2011 Feb; 5(1):33-59. PubMed ID: 21045018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of enoxaparin in emergency room for improving outcomes of primary percutaneous coronary interventions for acute myocardial infarction.
    Abhyankar AD; Pothiawala SE; Kazi GJ; Jha MJ; Petrolwala M
    Indian Heart J; 2008; 60(1):39-44. PubMed ID: 19212020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary intervention in patients with diabetes, chronic renal disease, and the elderly: therapeutic implications.
    Schneider DJ
    Rev Cardiovasc Med; 2007; 8 Suppl 3():S35-41. PubMed ID: 17917620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacoeconomics of deep vein thrombosis treatment.
    Shorr AF
    Am J Med; 2007 Oct; 120(10 Suppl 2):S35-41. PubMed ID: 17916458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial.
    Melloni C; Fier I; Roach J; Kosinski AS; Broderick S; Sigmon K; Myles S; Becker RC; Rao SV;
    Am Heart J; 2009 Nov; 158(5):726-33. PubMed ID: 19853689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options.
    Agnelli G; Caprini JA
    J Surg Oncol; 2007 Sep; 96(3):265-72. PubMed ID: 17474075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.